9 topics will be covered during ESOT TLJ 3.0 (colours will correspond across the programme)

	Machine perfusion in cardiothoracic transplantation
	Histopathological analysis of pre-implantation donor kidney biopsy: Redefining the Role in the Process of Graft Assessment (Part 1)
	The value of monitoring (subclinical) DSAs for kidney transplant outcomes
	Liver transplantation in patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD)
	Clinical Endpoints in liver transplantation according to value based care
	Downstaging, bridging and immunotherapy in liver transplantation for HCC
	Role of Pancreas Machine Perfusion to Increase the Donor Pool for beta cell replacement
	Prehabilitation for solid organ transplant candidates
	Molecular Biology Testing for Non-Invasive Diagnosis of Allograft Rejection

Programme of TLJ 3.0 is constructed based on the following session types:
- [EDU] - Educational Sessions which will give educational state-of-art lectures on the discussed topic
- [CONSENSUS] - Statements' presentations and discussions with participants. Statements will be developed based on work done prior to the meeting
- [VOTING] – Statement's that will be discussed during first part of the conference will be voted by audience

PARALLEL PROGRAMME – TLJ 3.0. Consensus Conference
SUNDAY, 13 November 2022

11:00 – 12:30 [EDU] Machine perfusion in cardiothoracic transplantation	Room: Club H
Chair(s): Luciano Potena | Bologna, Italy *Robin Vos | Leuven, Belgium*	

11:00 – 11:20	How to organize scientific innovation and training with machine perfusion in Europe: the COPE model	Rutger Ploeg | Oxford, United Kingdom
11:20 – 11:40	Organizing an Ex vivo lung perfusion program under a national perspective: the French experience	Julien de Wolf | Paris, France
11:40 – 12:00	A local centre perspective on Organizing Ex situ heart perfusion: the Italian experience	Sandro Sponga | Udine, Italy
12:00 – 12:30	PRO-CON debate we need/ do not need machine perfusion in thoracic transplantation	Irene Bello | Barcelona, Spain Bettina Wiegman | Hannover, Germany

11:00 – 12:30 [EDU] Role of Pancreas Machine Perfusion to Increase the Donor Pool for beta cell replacement	Room: Club D
Chair(s): Joana Ferrer | Barcelona, Spain	

11:00 – 11:20	Development of pancreatic machine perfusion: translational steps from porcine to human models	Vassilios Papalois | London, United Kingdom
11:20 – 11:40	Ischemia-Reperfusion Injuries assessment during Pancreatic machine Preservation for islet transplantation	Marten A Engelse | Leiden, Netherlands
11:40 – 12:00	Hypothermic oxygenated machine perfusion of the human pancreas for clinical islet isolation	Henri G. D. Leuvenink | Groningen, Netherlands
12:00 – 12:20	Pancreatic machine perfusion of the human pancreas: State of the art with future directions	Julien Branchereau | Nantes, France
12:20 – 12:30	Discussion on the mentioned topics	All speakers

11:00 – 12:30	Room: Club E
[EDU] Histopathological analysis of pre-implantation donor kidney biopsy: Redefining the Role in the Process of Graft Assessment (part1)	
*Chair(s): Lucrezia Furian	Padova, Italy* *Gianluigi Zaza	Verona, Italy*	

11:00 – 11:05	Introduction	Gianluigi Zaza	Verona, Italy
11:05 – 11:25	Pre-implantation kidney biopsy: does it increase or reduce the organ utilization?	Lorna Marson	Edinburgh, United Kingdom
11:25 – 11:45	T0 kidney biopsy: how useful from a clinical perspective?	David Cucchiari	Barcelona, Spain
11:45 – 12:05	Kidney biopsy must be representative: let's do it better	Albino Eccher	Verona, Italy
12:05 – 12:25	Data of interest in the pre-implantation kidney biopsy	Marion Rabant	Paris, France
12:25 – 12:30	Q&A to presentations above	All speakers

11:00 – 12:30	Room: Club A
[EDU] Liver transplantation in patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD)	
*Chair(s): Luca Belli	Milan, Italy* *Silvio Nadalin	Tübingen, Germany*	

11:00 – 11:05	Introduction	Luca Belli	Milan, Italy Silvio Nadalin	Tübingen, Germany
11:05 – 11:25	Introduction lecture: Pathophysiology of primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD)	Johannes Hov	Oslo, Norway
11:25 – 11:40	Case scenario #1 on PSC & IBD	TBC
11:40 – 11:55	Case scenario #2 on PSC & IBD	Chiara Mazzarelli	Milan, Italy
11:55 – 12:10	Case scenario #3 on PSC & IBD	Andrea Della Penna	Tübingen, Germany
12:10 – 12:30	Discussion panel on mentioned topics	All speakers

12:30 – 13:30 LUNCH BREAK

13:30 – 15:00   Room: Club H
[EDU] Prehabilitation for solid organ transplant candidates

Chair(s): Diethard Monbaliu | Leuven, Belgium
Sharlene Greenwood | London, United Kingdom

13:30 – 13:35	Welcome	Diethard Monbaliu	Leuven, Belgium Sharlene Greenwood	London, United Kingdom
13:35 – 13:50	Introduction on prehabilitation	Sunita Mathur	Kingston, Canada
13:50 – 14:00	Example prehabilitation oncological surgery	Joost Klaasen	Groningen, Netherlands
14:00 – 14:10	Example prehabilitation kidney and lung transplant candidates	Tania Januadis- Ferreira	Montreal, Canada
14:10 – 14:25	Example nutritional intervention	Christophe Matthys	Leuven, Belgium
14:25 – 14:40	Example psychological intervention	Fabienne Dobbels	Leuven, Belgium
14:40 – 14:50	Assessment prior to prehabilitation	Evangelia Kouidi	Thessaloniki, Greece
14:50 – 15:00	Frailty in solid organ transplant candidates	Maria Jose Perez Saez	Barcelona, Spain

13:30 – 15:00   Room: Club E
[EDU] The value of monitoring (subclinical) DSAs for kidney transplant outcomes

Chair(s): Soufian Meziyerh | Leiden, Netherlands
Aiko de Vries | Leiden, Netherlands

13:30 – 13:55	Introduction to donor specific antibodies	Marie Paul Emonds	Leuven, Belgium
13:55 – 14:20	The clinical implications of DSA monitoring	Dennis van den Broek	Leiden, Netherlands
14:20 – 14:45	Are we finally ready for personalized therapeutic drug monitoring with novel immunological risk stratification?	Soufian Meziyerh	Leiden, Netherlands

| 14:45 – 15:00 | Update on the upcoming recommendations of the Sensitization in Transplantation: Assessment of Risk (STAR) working group. | Carmen Lefaucheur \| Paris, France |

13:30 – 15:00
[EDU] Clinical Endpoints in liver transplantation according to value based care

Chair: Umberto Cillo | Padova, Italy
Karen Rockell | London, United Kingdom

Room: Club A

13:30 – 13:45	Value Based Health care: what does it mean?	Mario Strazzabosco | New Haven, USA
13:45 – 14:00	Why is it crucial to change the metrics in liver transplantation? From procedure to process outcomes, from volume to value (includes discussion of the liver transplantation benefit concept)	Umberto Cillo | Padova, Italy
14:00 – 14:15	Metrics to evaluate transplant programs	James Neuberger | Birmingham, United Kingdom
14:15 – 14:30	The patients' perspective: the concepts of PROMS and PREMS	Karen Rockell | London, United Kingdom
14:30 – 14:45	Quality of life metrics in liver transplantation	Lorenzo Mantovani | Milan, Italy
14:45 – 15:00	Discussion panel on mentioned topics	All speakers

15:00 – 15:30 COFFEE BREAK

15:30 – 17:00
[EDU] Molecular Biology Testing for Non-Invasive Diagnosis of Allograft Rejection

Chair(s): Luciano Potena | Bologna, Italy
Marina Berenguer | Valencia, Spain

Room: Club H

| 15:30 – 15:35 | Presentation of the project and structure of the meeting | Luciano Potena \| Bologna, Italy |
| 15:35 – 15:50 | Current challenges in personalizing immunosuppression | Oriol Bestard \| Barcelona, Spain |

15:50 – 16:05	A portrait of the ideal biomarker to guide clinical decision making in transplantation: ideal targets and available tools	Valeria Mas	Maryland, USA
16:05 – 16:20	Gene expression profiling: technical concepts, limitations and what is available on the market	John Friedewald	Chicago, USA
16:20 – 16:35	Cell free DNA: technical concepts, limitations and what is available on the market	Sean Agbor-Enoh	USA
16:35 – 17:00	Panel Discussion	Kiran Kush	Stanford, USA, Dany Anglicheau|Paris, France, Robin Vos	Leuven, Belgium, Marisa Crespo Leiro	A Coruña, Spain

15:30 – 17:00 **[EDU] Immunomodulation and desensitization in kidney transplantation** *Chair(s): Lucrezia Furian	Padova, Italy* *Olivier Thaunat	Lyon, France*	Room: Club E

15:30 – 15:40	Stratification risk of sensitized transplant candidates: The ENGAGE part 1 WG	Olivier Thaunat	Lyon, France
15:40 – 15:50	ENGAGE part 2 WG: Desensitization and immunomodulation of sensitized kidney transplant recipients	Lucrezia Furian	Padova, Italy
15:50 – 16:00	ENGAGE consensus project: Delphi methodology for reaching consensus in a low-evidence setting	Fabio Vistoli	Pisa, Italy
16:00 – 16:15	Desensitization in HLA-incompatible kidney transplant recipients: how and when	Fritz Diekmann	Barcelona, Spain
16:15 – 16:30	Induction approaches for sensitized kidney transplant recipients	Soren Sorensen	Copenhagen, Denmark
16:30 – 16:45	Maintenance therapy strategies in patients with different immunological risk	Klemens Budde	Berlin, Germany
16:45 – 16:55	What role for complement inhibitors: where consensus lacks	Marteen Naesens	Leuven, Belgium
16:55 – 17:00	Questions and discussion	

15:30 – 17:00 **[EDU] Downstaging, bridging and immunotherapy in liver transplantation for HCC** *Chair(s): Christian Toso	Geneva, Switzerland* *Parissa Tabrizian	New York, USA*		Room: Club A
15:30 – 15:45	Transplantation in the global management of HCC: how far can we go thanks to downstaging?	Gonzalo Sapisochin | Toronto, Canada
15:45 – 16:00	Practical framework of downstaging process: results from recent evidences	Sherrie Bhoori | Milan, Italy
16:00 – 16:15	Locoregional HCC treatments in the context of bridging/downstaging	Umberto Cillo | Padova, Italy
16:15 – 16:30	Systemic/immunotherapy HCC treatment in the context of bridging/downstaging	Maria Reig | Barcelona, Spain
16:30 – 17:00	Panel discussion on mentioned topics	All

17:00 – 17:30 COFFEE BREAK

17:30 – 19:00 **[CONSENSUS] Liver transplantation in patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) SESSION 1** *Chair(s): Luca Belli	Milan, Italy* *Silvio Nadalin	Tübingen, Germany*		Room: Club A
17:30 – 17:50	Timing, indication and allocation rules of liver transplantation *- Is the Meld-based allocation scheme a disadvantage for patients with PSC? (WL mortality in PSC vs non-PSC)* *- Is pre-emptive LT for high-grade dysplasia in suspicious strictures indicated and compatible with the overall demand of LT? (Screening for CAA - who, when, how? PET scan?*	Eleonora De Martin | Paris, France
17:50 – 18:10	Management on wait-list *- Is the prophylactic use of rotating antibiotic for recurrent cholangitis safe in view of LT? (emergence of MDR bacteria)* *- Indication and timing of biliary stenting? (who, when, how)*	Annika Bergquist | Stockholm, Sweden

18:10 – 18:30	Graft Selection and Technical issues *- Biliary reconstruction: duct-to-duct anastomosis vs to Roux-en-Y hepaticojejunostomy (post-LT cholangitis, late-onset NAS, graft survival)?* *- Is the use of ECD (including DCD) in PSC associated with higher rate of NAS compared to other LT indications?*	Pal Dag Line | Oslo, Norway
18:30 – 19:00	Discussion & Consensus Recommendations	All speakers

18:30 – 19:30 NETWORKING EVENT

MONDAY, 14 November 2022

08:00 – 09:00 **Opening Session** *Chair(s): Umberto Cillo	Padova, Italy* *Raj Thuraisingham	London, United Kingdom*	Room: Panorama

08:00 – 08:10	Welcome to TLJ 3.0.	Umberto Cillo	Padova, Italy Raj Thuraisingham	London, United Kingdom
08:10 – 08:35	Sir Peter Morris lecture: ESOT in a global transplant world	Gabriel Oniscu	Edinburgh, United Kingdom
08:35 – 09:00	Introduction to consensus methodology for TLJ 3.0	Umberto Cillo	Padova, Italy Annemarie Weissenbacher	Innsbruck, Austria

09:00 – 09:15 BREAK / MOVE TO BREAKOUT ROOMS

09:15 – 10:45 **[CONSENSUS] Liver transplantation in patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) SESSION 2** *Chair(s): Luca Belli	Milan, Italy* *Silvio Nadalin	Tübingen, Germany*	Room: Club A

09:15 – 09:35	**Immunosuppression strategy** *- Is CyA-Aza based better than Tac-MMF-based IS regimen on graft outcomes? (rate of ACR, LAR, CR, recPSC, bowel safety, IBD)*	James Neuberger	Birmingham, United Kingdom
09:35 – 09:55	**Management of IBD in PSC patients** *- prophylactic colectomy in UC patients: indication, timing (before, during, after LT) and other potential surgical solutions (colectomy + end ileostomy vs colectomy + IPAA ()* *- Best monitoring strategy before and after LT? (silent RCU? CRC screening? Anti-TNF? Vedo-ustek?)*	Palak Trivedi	Birmingham, United Kingdom
09:55 – 10:15	**Avoiding PSC recurrence (strategies)** *- Should LT recipients for PSC/IBD be monitored with regular histological follow up (liver and intestine) to*	Marco Carbone	Milan, Italy

capture the first signs of disease reactivation which could be potentially treated with experimental drugs in appropriately designed studies?
- Are there criteria of futility for re-OLT?

10:15 – 10:45	Discussion & Consensus Recommendations	All speakers

09:15 – 10:45	**Room: Club E**
[CONSENSUS] Histopathological analysis of pre-implantation donor kidney biopsy: Redefining the Role in the Process of Graft Assessment (Part 1) **SESSION 1**	
*Chair(s): Lucrezia Furian	Padova, Italy* *Gianluigi Zaza	Verona, Italy* *David Cucchiari	Barcelona, Spain*	

09:15 – 09:40	For the evaluation of chronic lesions in ECD kidneys, is the needle core biopsy comparable/inferior/superior to wedge biopsy or punch biopsies (with a skin puncher as in PMID 22492825) in terms of representativity of the entire renal parenchyma?	Marion Rabant	Paris, France
09:40 – 10:05	For the evaluation of chronic lesions in ECD kidneys, is the frozen section comparable/inferior/ superior to paraffin embedded section in terms of reliability of the reading from pathologists?	Jesper Kers	Amsterdam, Netherlands
10:05 – 10:30	For score assessment of pre-implantation kidney biopsy in the evaluation of ECD is the experienced renal pathologist comparable/inferior/superior to on-call pathologist in terms of reproducibility and accuracy of the histological report?	Jan Becker	Koeln, Germany
10:30 – 10:45	In the quantification of the chronic damage in ECD kidneys, is glomerulosclerosis more reproducible in comparison with other parameters (interstitial fibrosis, tubular atrophy, wall/lumen ratio, arteriolar hyalinosis)?	Marion Rabant	Paris, France

09:15 – 10:45	**Room: Club H**
[CONSENSUS] Machine perfusion in cardiothoracic transplantation **SESSION 1 (HEART)**	
*Chair: Martin Schweiger	Zurich, Switzerland* *Bettina Wiegman	Hannover, Germany*	

09:15 – 09:35	PICO Heart 1: In heart transplantation, for which heart should machine perfusion be performed	Sandro Sponga	Udine, Italy

09:35 – 09:55	PICO Heart 2: In heart transplantation, which protocol should be used for machine perfusion	Stephen Clark | Newcastle, UK
09:55 – 10:15	PICO Heart 3: In heart transplantation, which parameters should be used to determine graft quality during ex vivo heart perfusion	Cristiano Amarelli | Naples, Italy
10:15 – 10:35	PICO Heart 4: In heart transplantation, which recipients should benefit from a heart assessed by machine perfusion	Stephan Ensminger | Lübeck, Germany
10:35 – 10:45	Discussion	All speakers

09:15 – 10:45		Room: Club D
[CONSENSUS] Prehabilitation for solid organ transplant candidates SESSION 1		
Chair: Diethard Monbaliu | Leuven, Belgium *Sharlene Greenwood | London, UK*		
09:15 – 09:20	Welcome	Sharlene Greenwood | London, UK Diethard Monbaliu | Leuven, Belgium
09:20 – 10:05	Evidence regarding exercise in solid organ transplant candidates	Stefan De Smet | Leuven, Belgium
10:05 – 10:20	Discussion and recommendations	All speakers

10:45 – 11:15 COFFEE BREAK

11:15 – 12:45		Room: Club A
[CONSENSUS] Clinical Endpoints in liver transplantation according to value based care SESSION 1		
Chair: Mario Strazzabosco | New Haven, USA *Umberto Cillo | Padova, Italy*		
11:15 – 11:45	Which is the best single measure to evaluate liver transplantation process as a whole from the VBC perspective?	Umberto Cillo | Padova, Italy
11:45 – 12:15	When gain in life years or reduction in years lost are not available/calculable which is the best measure to describe the transplant process from a VBM perspective?	Marco Carbone | Milan, Italy

12:15 – 12:45	In Liver transplant recipients which is the best tool to adjust for quality of life the life gain of liver transplantation?	James Neuberger | Birmingham, United Kingdom

11:15 – 12:45 [CONSENSUS] Histopathological analysis of pre-implantation donor kidney biopsy: Redefining the Role in the Process of Graft Assessment (Part 1) SESSION 2 *Chair: Lucrezia Furian | Padova, Italy Gianluigi Zaza | Verona, Italy*		Room: Club E
11:15 – 11:40	In the quantification of the chronic damage in ECD kidneys is measurement of histological variables with digital pathology comparable/inferior/superior if compared with light microscopy?	Albino Eccher| Verona, Italy
11:40 – 12:05	In the quantification of the chronic damage in ECD kidneys is measurement of histological variables with the aid of special stainings (PAS/Trichromic/Silver) comparable/inferior/superior if compared with H&Eosin alone?	Jesper Kers | Amsterdam, Netherlands
12:05 – 12:30	In the quantification of the chronic damage in ECD kidneys, is glomerulosclerosis percentage more representative than other parameters (interstitial fibrosis, tubular atrophy, arteriolar hyalinosis and cv score) to predict the graft survival, graft function, primary non-function?	Michele Rossini | Bari, Italy
12:30 – 12:45	Final remarks	Gianluigi Zaza | Verona, Italy Lucrezia Furian | Padova, Italy

11:15 – 12:45 [CONSENSUS] Machine perfusion in cardiothoracic transplantation SESSION 2 (LUNG) *Chair(s): Massimo Boffini | Turin, Italy Marita Dalvindt | Lund, Sweden*		Room: Club H
11:15 – 11:35	PICO Lung 1: In lung transplantation, for which lung should ex vivo lung perfusion be performed	De Wolf Julien | Nantes, France
11:35 – 11:55	PICO Lung 2: In lung transplantation, which protocol should be used for ex vivo lung perfusion	Clemens Aigner | Essen, Germany

11:55 – 12:15	PICO Lung 3: In lung transplantation, which parameters should be used to determine graft quality during ex vivo lung perfusion	Lucas Hoyos	Madrid, Spain
12:15 – 12:35	PICO Lung 4: In lung transplantation, which recipients should benefit from a lung assessed by ex vivo lung perfusion	Irene Bello	Barcelona, Spain

11:15 – 12:45 **[CONSENSUS] Prehabilitation for solid organ transplant candidates SESSION 2** *Chair: Diethard Monbaliu	Leuven, Belgium Sharlene Greenwood	London, UK*	Room: Club D

11:15 – 11:20	Welcome	Sharlene Greenwood	London, UK Diethard Monbaliu	Leuven, Belgium
11:20 – 11:50	Evidence regarding nutritional interventions in solid organ transplant candidates	Yasna Overloop	Leuven, Belgium
11:50 – 12:05	Discussion and recommendations	All speakers
12:05 – 12:35	Evidence regarding psychosocial interventions in solid organ transplant candidates	Ellen Castle	London, UK
12:35 – 12:50	Discussion and recommendations	All speakers

12:45 – 13:45 LUNCH BREAK

13:45 – 15:15 **[CONSENSUS] Clinical Endpoints in liver transplantation according to value based care SESSION 2** *Chair: Wojtek Polak	Rotterdam, Netherlands Umberto Cillo	Padova, Italy*	Room: Club A

13:45 – 14:10	Which are the unmet needs in defining the critical PROMs and PREMs to be included in liver transplant "core" evaluation and clinical trial design?	Ian Rowe	Leeds, UK
14:10– 14:30	What is the most appropriate time frame to assess liver transplant outcomes from a VBM perspective?	Marco Carbone	Milan, Italy Costantino Fondevila	Madrid, Spain

14:30– 14:50	In a setting with optimal potential candidate referral and listing process, which is the best measure to evaluate the quality of waiting list management in a VBHM perspective?	Mario Strazzabosco | New Haven, USA
14:50– 15:10	Which is the best metrics to describe the quality of early postoperative course?	Wojtek Polak | Rotterdam, Netherlands

13:45 – 15:15
[CONSENSUS] Role of Pancreas Machine Perfusion to Increase the Donor Pool for beta cell replacement
SESSION 1

Chair(s): Joana Ferrer | Barcelona, Spain
Julien Branchereau | Nantes, France

Room: Club D

13:45 – 14:15	Pancreatic transplantation (whole organ transplantation) Ex- situ hypothermic machine perfusion (HMP)	Benoît Mesnard | Nantes, France
14:15 – 14:45	Pancreatic transplantation (whole organ transplantation) Ex-situ normothermic machine perfusion (NMP)	Trevor Reichman | Toronto, Canada
14:45 – 15:15	Pancreatic transplantation (whole organ transplantation) In-situ normothermic machine perfusion (NMP)	Franka Messner | Innsbruck, Austria

13:45 – 15:15
[CONSENSUS] Molecular Biology Testing for Non-Invasive Diagnosis of Allograft Rejection (Kidney)
SESSION 1

Chair(s): John Friedewald | Chicago, USA

Room: Club H

13:45 – 14:15	dd-cfDNA Presentation	*Sook Park	USA*
14:15 – 14:45	GEP Presentation	Joana Sellares | Barcelona, Spain
14:45 – 15:15	Urine Chemokine Presentation	Claire Tinel | Dijon, France

13:45 – 15:15
[CONSENSUS] Molecular Biology Testing for Non-Invasive Diagnosis of Allograft Rejection (Heart & Lung)
SESSION 1

Chair(s): Luciano Potena | Bologna, Italy
Kiran Khush | Stanford, USA

Room: 220

13:45 – 13:55	Introduction and Survey results	Luciano Potena | Bologna, Italy

13:55 – 14:00	Discussion	
14:00 – 14:15	PICO 1/2 Heart: Are GEP and dd-cfDNA reliable methods to diagnose rejection?	Andriana Nikolova | , USA
14:15 – 14:30	Discussion	
14:30 – 14:40	PICO 1 Lung: Is ddcfDNA a reliable marker to diagnose/monitor acute rejection or infection of the graft in lung transplant patients ?	Sean Agbor-Enoh | USA
14:40 – 14:50	PICO 2 Lung: Is ddcfDNA a reliable therapeutic marker to monitor treatment response for acute rejection or infection of the graft in lung transplant patients?	Sean Agbor-Enoh | USA
14:50 – 15:15	Discussion	

13:45 – 15:15 **[CONSENSUS] Molecular Biology Testing for Non-Invasive Diagnosis of Allograft Rejection (Liver)** **SESSION 1** *Chair(s): Marina Berenguer | Valencia, Spain*	Room: 221

13:45 – 14:05	Biomarkers and HCC recurrence in liver transplantation	Marina Berenguer | Valencia, Spain
14:05 – 14:30	Discussion	Marina Berenguer | Valencia, Spain
14:30 – 14:50	Biomarkers and disease recurrence in liver transplantation	Eleonora De Martin | Paris, France
14:50 – 15:15	Discussion	Eleonora De Martin | Paris, France

13:45 – 15:15 **[CONSENSUS] The value of monitoring (subclinical) DSAs for kidney transplant outcomes** **SESSION 1** *Chair(s): Aiko de Vries | Leiden, Netherlands* *Dominique Bertrand | Rouen, France*	Room: Club E

13:45 – 13:50	Introduction	Dennis van den Broek | Leiden, Netherlands
13:50 – 13:55	Is there a health problem?	Aiko de Vries | Leiden, Netherlands

13:55 – 14:20	Do we understand the natural history of rejection sufficiently to identify a latent stage?	Carmen Lefaucheur | Paris, France
14:20 – 14:45	Are we able to identify latent rejection through DSA screening before graft dysfunction?	Marten Naesens | Leuven, Belgium
14:45 – 15:00	Are current DSA tests suitable for screening?	Marie Paul Emonds | Leuven, Belgium
15:00 – 15:15	Discussion	

15:15 – 15:45 COFFEE BREAK

15:45 – 17:15
[CONSENSUS] Downstaging, bridging and immunotherapy in liver transplantation for HCC
SESSION 1

Chair(s): Christian Toso | Geneva, Switzerland
Maria Reig | Barcelona, Spain

Room: Club A

15:45 – 16:03	Should all eligible patients be transplanted after successful downstaging?	Sherrie Bhoori | Milan, Italy
16:03 – 16:21	Should all patients outside transplant criteria (all comers) be considered for downstaging?	Christian Toso | Geneva, Switzerland
16:21 – 16:39	Should patients with complete response of HCC macrovascular invasion be considered for liver transplantation?	Gonzalo Sapisochin | Toronto, Canada
16:39 – 16:57	Does bridging decrease waitlist drop-out?	Marco Claasen | Rotterdam, Netherlands
16:57 – 17:15	Does bridging improve post-transplant survival?	Marco Claasen | Rotterdam, Netherlands

15:45 – 17:15
[CONSENSUS] Role of Pancreas Machine Perfusion to Increase the Donor Pool for beta cell replacement
SESSION 2

Chair: Paul Johnson | Oxford, United Kingdom
Marten A Engelse | Leiden, Netherlands

Room: Club D

15:45 – 16:10	Islet transplantation Ex- situ hypothermic machine perfusion (HMP)	Jason Doppenberg | Leiden, Netherlands
16:10 – 16:35	Islet transplantation Ex-situ normothermic machine perfusion (NMP)	Henri Leuvenink | Groningen, Netherlands

| 16:35 – 16:55 | Islet transplantation
In-situ normothermic machine perfusion (NMP) | Ann Etohan Ogbemudia \| Oxford, UK |
| 16:55 - 17:20 | Islet transplantation
Persufflation | Jason Doppenberg \| Leiden, Netherlands |

15:45 – 17:15 **[CONSENSUS] Molecular Biology Testing for Non-Invasive Diagnosis of Allograft Rejection (Kidney)** **SESSION 2** *Chair(s): John Friedewald | Chicago, USA*	Room: Club H

15:45 – 16:15	dd-cfDNA discussion	John Friedewald | Chicago, USA
16:15 – 16:45	GEP discussion	Oriol Bestard | Barcelona, Spain
16:45 – 17:15	Urine Chemokine discussion	Dany Anglicheau | Paris, France

15:45 – 17:15 **[CONSENSUS] Molecular Biology Testing for Non-Invasive Diagnosis of Allograft Rejection (Heart & Lung)** **SESSION 2** *Chair(s): Luciano Potena | Bologna, Italy* *Kiran Khush | Stanford, USA*	Room: 220

15:45 – 15:55	PICO 3 Heart: In heart transplant patients, is ddcfDNA (or GEP) reliable surveillance strategy to monitor for cardiac allograft vasculopathy as compared with standard diagnostic methods?	Andriana Nikolova | , USA
15:55 – 16:05	PICO 3 Lung Is ddcfDNA a reliable marker to stratify prognosis of lung transplant recipients for chronic lung allograft dysfunction (CLAD), as compared to standard clinical classifiers?	Robin Vos | Leuven, Belgium
16:05 – 16:25	Discussion	
16:25 – 16:35	PICO 4 Heart: In heart transplant patients with stable graft function, is ddcfDNA (or GEP) a reliable marker to stratify prognosis (or monitor the efficacy of therapy) as compared to standard clinical classifiers	Javier Segovia | Madrid, Spain
16:35 – 16:45	PICO 5 Heart: In heart transplant patients with stable graft function, are cardiac biomarkers (NT-proBNP, BNP, Troponin) reliable surveillance tool for subclinical acute	Marisa Crespo Leiro | A Coruña, Spain

	rejection monitoring, compared to endomyocardial biopsy?	
16:45 – 17:05	Discussion	

15:45 – 17:15 **[CONSENSUS] Molecular Biology Testing for Non-Invasive Diagnosis of Allograft Rejection (Liver)** **SESSION 2** *Chair(s): Marina Berenguer	Valencia, Spain*	Room: 221
15:45 – 16:05	Biomarkers and rejection in liver transplantation	Valeria Mas	Maryland, USA
16:05 – 16:30	Discussion	Valeria Mas	Maryland, USA
16:30 – 16:50	Biomarkers and kidney function in liver transplantation	Josh Levitsky	Chicago, USA
16:50 – 17:15	Discussion	Josh Levitsky	Chicago, USA

15:45 – 17:15 **[CONSENSUS] The value of monitoring (subclinical) DSAs for kidney transplant outcomes** **SESSION 2** *Chair(s): Aiko de Vries	Leiden, Netherlands* *Carmen Lefaucheur	Paris, France*	Room: Club E
15:45 – 16:00	Can certain DSA characteristics be used to guide allograft biopsy decision making?	Emanuele Cozzi	Padova, Italy
16:00 – 16:25	Is there a defined treatment for patients with subclinical DSA or subclinical rejection?	Klemens Budde	Berlin, Germany
16:25 – 16:35	Is DSA monitoring cost-effective?	Anthony Dorling	London, United Kingdom
16:35 – 17:00	Is there an optimal monitoring strategy?	Dominique Bertrand	Rouen, France
17:00 – 17:15	Discussion	

17:15 – 17:30 COFFEE BREAK

17:30 – 19:00   Room: Club A
[CONSENSUS] Downstaging, bridging and immunotherapy in liver transplantation for HCC
SESSION 2

Chair(s): Christian Toso | Geneva, Switzerland
Gonzalo Sapisochin | Toronto, Canada

17:30 – 17:45	Does the type of response to bridging have an impact on survival	Sherrie Bhoori	Milan, Italy
17:45 – 18:15	What is the best bridging/downstaging strategy?	Dimitri Sneiders	Birmingham, UK Bastiaan Rakke	Rotterdam, Netherlands
18:15 – 18:30	Are patients on immunotherapy prior to liver transplantation at higher risk of rejection?	Parissa Tabrizian	New York, USA
18:30 – 18:45	What is the best way to assess response to immunotherapy?	Parissa Tabrizian	New York, USA
18:45 – 19:00	What is the safety of the combined treatment with immunotherapy and loco-regional therapy (LRT)?	Maria Reig	Barcelona, Spain

TUESDAY, 15 November 2022

08:00 – 09:00	Room: Club A
[VOTING] Liver transplantation in patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD)	
*Chair(s): Luca Belli	Milan, Italy*	
*Silvio Nadalin	Tübingen, Germany*	

08:00 – 08:30	Consensus Statements Voting	Luca Belli	Milan, Italy Silvio Nadalin	Tübingen, Germany
08:30 – 08:45	Summary of gaps identified and collaborative research to answer	Marco Carbone	Milan, Italy

08:00 – 09:30	Room: Club E
[VOTING] Histopathological analysis of pre-implantation donor kidney biopsy: Redefining the Role in the Process of Graft Assessment (Part 1)	
*Chair(s): Lucrezia Furian	Padova, Italy*	
*Gianluigi Zaza	Verona, Italy*	

08:00 – 09:00	Consensus Statements Voting	David Cucchiari	Barcelona, Spain
09:00 – 09:30	Summary of gaps identified and collaborative research to answer	

08:00 – 09:30	Room: Club H
[VOTING] Machine perfusion in cardiothoracic transplantation	
*Chair: Sandro Sponga	Udine, Italy*	
*Arne Neyrinck	Leuven, Belgium*	

08:00 – 08:30	Statements on Machine Perfusion of the Lung	David Gomez	Madrid, Spain
08:30 – 09:00	Statements on Machine Perfusion of the Heart	Bettina Wiegmann	Hannover, Germany
09:00 – 09:20	Controversial issues in Machine Perfusion of the Lung & Heart	Arne Neyrinck	Leuven, Belgium
09:20 – 09:30	Controversial issues: messages from recipients	Marita Dalvindt	Lund, Sweden

08:00 – 09:30 **[VOTING] Prehabilitation for solid organ transplant candidates** *Chair: Diethard Monbaliu | Leuven, Belgium* *Sharlene Greenwood | London, United Kingdom*	Room: Club D
08:00 – 09:00 Consensus Statements Voting	Diethard Monbaliu | Leuven, Belgium Sharlene Greenwood | London, United Kingdom
09:00 – 09:30 Summary of gaps identified and collaborative research to answer knowledge gap	Diethard Monbaliu | Leuven, Belgium

09:00 – 09:30 **[VOTING] Clinical Endpoints in liver transplantation according to value based care | PART 1** *Chair: Marco Carbone | Milan, Italy* *Umberto Cillo | Padova, Italy*	Room: Club A
09:00 – 09:30 Consensus Statements Voting	Marco Carbone | Milan, Italy Umberto Cillo | Padova, Italy

09:30 – 09:45 BREAK

09:45 – 10:15 **[VOTING] Clinical Endpoints in liver transplantation according to value based care | PART 2** *Chair: Marco Carbone | Milan, Italy* *Umberto Cillo | Padova, Italy*	Room: Club A
09:45 – 10:15 Consensus Statements Voting Summary of gaps identified and collaborative research to answer	Marco Carbone | Milan, Italy Umberto Cillo | Padova, Italy

09:45 – 11:15
[VOTING] Role of Pancreas Machine Perfusion to Increase the Donor Pool for beta cell replacement

Room: Club D

Chair(s): Joana Ferrer | Barcelona, Spain
Julien Branchereau | Nantes, France

09:45 – 10:30	Pancreatic transplantation (whole organ transplantation)	Benoit Mesnard	Nantes, France
10:30 – 11:15	Islet transplantation	Marten A Engelse	Leiden, The Netherlands Jason Doppenberg	Leiden, The Netherlands

09:45 – 11:15
[VOTING] Molecular Biology Testing for Non-Invasive Diagnosis of Allograft Rejection

Room: Club H

Chair: Luciano Potena | Bologna, Italy
Marina Berenguer | Valencia, Spain

09:45 – 11:15	Voting on consensus statements (Kidney)	John Friedewald	Chicago, USA
10:15 – 10:45	Voting on consensus statements (Liver)	Marina Berenguer	Valencia, Spain
10:45 – 11:15	Voting on consensus statements (Lung & Heart)	Luciano Potena	Bologna, Italy Sean Agbor-Enoh	USA

09:45 – 11:15
[VOTING] The value of monitoring (subclinical) DSAs for kidney transplant outcomes

Room: Club E

Chair(s): Aiko de Vries | Leiden, Netherlands
Anthony Dorling | London, United Kingdom

09:45 – 11:15	Voting on consensus statements for the topic	Dennis Van Den Broek	Leiden, Netherlands Soufian Meziyerh	Leiden, Netherlands

10:15 – 11:15	Room: Club A
[VOTING] Downstaging, bridging and immunotherapy in liver transplantation for HCC	
*Chair(s): Christian Toso	Geneva, Switzerland* *Umberto Cillo	Padova, Italy*	

10:15 – 11:15	Voting on consensus statements for the topic

11:15 – 11:45 COFFEE BREAK

11:45 – 12:45	Room: Panorama
Closing Session *Chair(s): Umberto Cillo	Padova, Italy* *Raj Thuraisingham	London, United Kingdom*	

11:45 – 12:00	TLJ 3.0 summary	Umberto Cillo	Padova, Italy
12:00 – 12:05	Outcome presentation: Machine perfusion in cardiothoracic transplantation	Cristiano Amarelli	Naples, Italy Arne Neyrinck	Leuven, Belgium
12:05 – 12:10	Outcome presentation: Histopathological analysis of pre-implantation donor kidney biopsy: Redefining the Role in the Process of Graft Assessment (Part 1)	Lucrezia Furian	Padova, Italy Gianluigi Zaza	Verona, Italy
12:10 – 12:15	Outcome presentation: The value of monitoring (subclinical) DSAs for kidney transplant outcomes	Aiko de Vries	Leiden, Netherlands
12:15 – 12:20	Outcome presentation: Liver transplantation in patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD)	Luca Belli	Milan, Italy Silvio Nadalin	Tübingen, Germany
12:20 – 12:25	Outcome presentation: Clinical Endpoints in liver transplantation according to value based care	Mario Strazzabosco	New Haven, USA
12:25 – 12:30	Outcome presentation: Downstaging, bridging and immunotherapy in liver transplantation for HCC	Christian Toso	Geneva, Switzerland
12:30 – 12:35	Outcome presentation: Role of Pancreas Machine Perfusion to Increase the Donor Pool for beta cell replacement	Joana Ferrer	Barcelona, Spain
12:35 – 12:40	Outcome presentation: Prehabilitation for solid organ transplant candidates	Diethard Monbaliu	Leuven, Belgium
12:40 – 12:45	Outcome presentation: Molecular Biology Testing for Non-Invasive Diagnosis of Allograft Rejection	Luciano Potena	Bologna, Italy